Merck
HomeServicesCustom Product DevelopmentContract ZooMAb® Antibody Development Services

Contract ZooMAb® Antibody Development Services

Conceptual image of a ZooMAb® recombinant antibody used in ZooMAb® contract antibody development services.

Contract ZooMAb® antibody development services are the solution for generating antibodies for your desired targets to meet your research and production needs. This service takes advantage of extensive expertise in immunogen design and preparation, antibody development and screening, application-specific testing, and antibody manufacturing at the scale that is relevant to your goals.

Request Service

Why Use Contract ZooMAb® Antibody Development?

Unlike conventional monoclonal and polyclonal technologies, ZooMAb® recombinant antibodies are developed from a proprietary B cell immortalization and recombinant expression platform using tissue culture-based methods. These stable immortalized cell lines provide extensive clonal selection and preserve immunization diversity. In contrast, other recombinant antibody development methods require immediate cloning to ensure clone viability, limiting the number of clones for further screening which results in the loss of highly specific candidates and creates the need for reimmunization.

The antibodies developed using our award-winning innovative technology exhibit lot-to-lot consistency, reproducibility, and application performance with the option to formulate the final buffer presentation for your specific downstream applications. With expert technical support, our contract ZooMAb® antibody development service offers excellent success rates and is scalable for your needs.

How ZooMAb® Antibodies Are Developed for Your Success

  • Robust Clonal Selection: Clones are pre-selected using a cell sorter, then screened in initial applications (i.e., ELISAs and Luminex® assays). The final candidates are subsequently tested in your desired application(s) to confirm specificity and sensitivity.
  • Highly Specific Candidates: The stable immortalized cell line enables the extensive clonal selection process and preserves the diversity from the initial immunization.
  • Reliable Success Rate: A significantly higher immortalization rate compared to the typical rabbit hybridoma fusion rate provides a wide diversity of clones, increasing the likelihood of finding the desired clone for your application.
  • In-House Expertise: Save time and effort by leveraging our technical expertise in assay development such as designing immunogen, sandwich, and Luminex® assays.

See how they compare to the traditional hybridoma approach.


Request Service


Comparing the ZooMAb® Approach to Traditional Methods

Table 1.Comparison of the development of conventional monoclonal antibodies to ZooMAb® recombinant antibodies. The proprietary ZooMAb® method achieves a high immortalization rate (80-90%) compared to the typical rabbit hybridoma fusion rate (<1%), providing highly specific clones and preserving diversity.

Typical Antibody Development Timeline

  • 5 – 6 weeks
    • 10 – 11 weeks
      • 10 – 12 weeks
        • 2 – 3 weeks
          • 6 – 7 weeks
          • Typically at a 0.5 – 1 mg scale
            • Depends on scale



              Sign In To Continue

              To continue reading please sign in or create an account.

              Don't Have An Account?